Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech, Amgen settle Neupogen dispute

Executive Summary

Amgen will make a one-time payment to Genentech as part of a Neupogen and Neulasta patent dispute settlement reached Aug. 26. The terms of the settlement were not disclosed, but Genentech's expectation of a $0.20 per-share impact during the third quarter suggests a payment of approximately $105 mil. after taxes. Both sides have agreed to drop all claims and counterclaims. Amgen said it is not taking a license to any of the three disputed Genentech patents (1"The Pink Sheet" Nov. 11, 1996, T&G-3)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS042391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel